Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: A South-Bronx experience

BACKGROUND: Monoclonal antibody therapy (MAT) is recommended in mild to moderate Coronavirus disease 2019 (COVID-19) patients who are at risk of progressing to severe disease. Due to limited data on its outcomes and the logistic challenges in administering the drug, MAT has not been widely used in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chilimuri, Sridhar, Mantri, Nikhitha, Gurjar, Hitesh, Youthjug, Karnokjun Annie, Sun, Haozhe, Gongati, Sudharsan, Zahid, Maleeha, Ronderos, Diana Maria, De La Cruz, Angel, Varanasi, Paavana, Shin, Dongmin, Nayudu, Suresh Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. on behalf of National Medical Association. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8433571/
https://www.ncbi.nlm.nih.gov/pubmed/34521513
http://dx.doi.org/10.1016/j.jnma.2021.08.036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8433571/
https://www.ncbi.nlm.nih.gov/pubmed/34521513
http://dx.doi.org/10.1016/j.jnma.2021.08.036

Ejemplares similares